SCHEMBL10241487

SCHEMBL10241487

COc1ccc(-c2[nH]nnc2-c2cc(OC)c(OC)c(OC)c2)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
NEK2 P51955 4/20 0.44
KDM4E B2RXH2 5/20 0.44
HPGD P15428 4/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
TUBB4A P04350 2/20 0.41
TUBB P07437 2/20 0.41
TUBA3C P0DPH7 2/20 0.41
TUBA1B P68363 2/20 0.41
TUBA4A P68366 2/20 0.41
TUBB4B P68371 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412935 0.99 LMNA (0.47) LMNATP53MAPTNEK2KDM4E
SCHEMBL13041092 0.91 KDM4E (0.41) LMNATP53MAPTKDM4EHPGD
SCHEMBL412934 0.89 KDM4E (0.40) LMNATP53MAPTKDM4EHPGD
SCHEMBL411645 0.89 MAPT (0.44) LMNATP53MAPTKDM4EHPGD
SCHEMBL412887 0.85 NEK2 (0.52) LMNATP53MAPTNEK2SMN1; SMN2
SCHEMBL3304869 0.83 RXFP1 (0.40) LMNATP53MAPTKDM4EHPGD
SCHEMBL410489 0.83 TUBB4A (0.58) KDM4EHPGDALDH1A1MEN1MAPK1
SCHEMBL3297139 0.82 ALDH1A1 (0.45) LMNATP53MAPTKDM4EHPGD
SCHEMBL411316 0.81 ALDH1A1 (0.44) LMNATP53MAPTKDM4EHPGD
SCHEMBL413893 0.81 ADORA3 (0.46) LMNATP53KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed
US-20100279410-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2010-11-04 US disclosed
US-7781462-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2010-08-24 US disclosed
US-20070238699-A1 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238699-A1 Compounds for the treatment of proliferative disorders RB1, MKI67, MAPRE1 LMNA 2274/4885TP53 25/4885MAPT 95/4885
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 LMNA 2274/4885TP53 25/4885MAPT 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.